|
시장보고서
상품코드
2086139
안과용 레이저 시장 : 레이저 기술별, 도입 형태별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)Ophthalmic Lasers Market by Laser Technology, Deployment Mode, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
안과용 레이저 시장은 2032년까지 연평균 복합 성장률(CAGR) 5.42%로 성장이 전망되며, 20억 9,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 14억 4,000만 달러 |
| 추정 연도 : 2026년 | 15억 2,000만 달러 |
| 예측 연도 : 2032년 | 20억 9,000만 달러 |
| CAGR(%) | 5.42% |
안과용 레이저는 망막, 녹내장, 각막, 백내장 및 굴절 교정 수술에서 정밀한 광응고, 광파괴, 광절제 및 선택적 조직 표적화를 가능하게 함으로써 현대 안과 의료에서 중심적인 역할을 수행하고 있습니다. 이러한 수요는 예방 가능한 시력 상실이라는 전 세계적 과제에 의해 구조적으로 뒷받침되고 있습니다. 세계보건기구(WHO)의 보고에 따르면, 최소 22억 명이 근시 또는 원시와 같은 시력 장애를 겪고 있으며, 이 중 최소 10억 건은 예방 가능하거나 아직 치료받지 못한 상태입니다.
이 시장은 고령화, 당뇨병 유병률 증가, 외래 수술 인프라 확충, 그리고 최소 침습 안과 수술을 선호하는 환자 경향에 의해 형성되고 있습니다. 주요 안과용 레이저 기술로는 펨토초 레이저, 엑시머 레이저, Nd:YAG 시스템, 다이오드 레이저, 선택적 레이저 섬유주대 성형술 플랫폼, 패턴 스캐닝 레이저, 그리고 새롭게 등장한 영상 유도 레이저 시스템 등이 있습니다. 제조업체, 유통업체, 의료 서비스 제공업체에게 있어 경쟁사와의 차별화는 임상적 정확도, 워크플로우 효율성, 시스템 가동률, 소프트웨어 통합, 규제 준수, 그리고 근거에 기반한 치료 성과에 점점 더 의존하게 되고 있습니다.
안과용 레이저 분야는 단일 에너지 플랫폼에서 디지털로 통합된 시술 특화형 생태계로 전환되고 있습니다. 망막 진료에서는 치료의 일관성을 높이기 위해 패턴 스캐닝이나 내비게이션을 이용한 광응고술이 채택되고 있는 반면, 녹내장 전문의들은 적절한 환자에게서 개방각 녹내장의 1차 치료법 또는 조기 개입 옵션으로서의 역할을 뒷받침하는 근거에 기반하여, 선택적 레이저 섬유주 성형술을 계속해서 사용하고 있습니다.
인공지능(AI)은 임상적 판단을 대체하는 것이 아니라, 안과용 레이저의 전체 밸류체인에 누적 영향을 미치고 있습니다. AI를 활용한 영상 분석은 당뇨병성 망막병증, 노화성 황반변성, 녹내장 및 전안부 평가 분야에서 폭넓게 연구되고 있으며, 레이저 치료에 앞서 보다 정확한 환자 선정과 치료 계획 수립의 기반을 마련하고 있습니다.
아시아태평양은 방대한 인구, 백내장 및 굴절 교정에 대한 높은 수요, 당뇨병 유병률 증가, 그리고 민간 안과 병원의 급속한 확장이 맞물리면서 안과용 레이저에 있어 가장 중요한 도입 환경 중 하나가 되고 있습니다. 중국, 인도, 일본, 한국, 호주 및 아세안 시장에서는 3차 안과 의료 센터, 전문 체인, 대학 병원, 그리고 첨단 굴절 교정 수술을 제공하는 기관을 통해 도입이 추진되고 있습니다.
인도네시아, 태국, 베트남, 말레이시아, 싱가포르, 필리핀이 전문 의료 체계를 확충하는 가운데, 아세안(ASEAN)은 안과용 레이저 분야의 전략적 클러스터로 부상하고 있습니다. 싱가포르는 선진적인 임상 도입 및 연수의 거점으로 자리매김하고 있는 반면, 인구가 많은 시장에서는 백내장, 당뇨병성 안과 질환, 녹내장 및 굴절 교정에 대한 수요가 시장을 주도하고 있습니다.
미국은 안과 의료 제공업체의 기반이 넓고, 선진적인 외래 수술 생태계, 활발한 의료기기 규제 승인 절차, 그리고 망막, 녹내장, 백내장, 굴절 교정 수술에 대한 수요가 높기 때문에 안과용 레이저 분야에서 가장 유망한 국가로 꼽히고 있습니다. 캐나다는 전문 의료 서비스의 도입이 안정적이고 임상 거버넌스도 탄탄하다는 점이 특징이며, 멕시코는 민간 부문의 안과 분야 투자와 국경을 초월한 의료 동향의 혜택을 누리고 있습니다. 브라질은 라틴아메리카 최대의 의료 시장이며, 망막 및 백내장 레이저 기술의 주요 도입국입니다.
업계 선도 기업들은 빈번하게 시행되는 모든 안과 수술 분야에서 정밀도, 안전성, 처리 능력, 재현성을 향상시키는 임상적으로 차별화된 안과용 레이저 플랫폼을 우선적으로 도입해야 합니다. 제품 전략은 특히 백내장, 당뇨병성 망막병증, 녹내장, 망막 질환, 굴절 이상과 같은 주요 질병 부담에 맞추어 수립되어야 합니다.
본 요약본은 검증된 공개 정보 및 업계에서 인정받는 정보 출처에 중점을 둔 체계적인 2차 조사 기법을 활용하여 작성되었습니다. 입력 데이터에는 세계 보건 기구의 역학 데이터, 인구 통계 지표, 의료기기 규제 체계, 임상 실무 동향, 안과학회의 지침, 동료 심사를 거친 문헌, 제품 승인 현황 및 의료 인프라 지표가 포함됩니다.
시력 장애, 당뇨병 관련 망막 질환, 녹내장, 백내장 및 굴절 교정에 대한 수요가 안과 의료 시스템에 계속해서 부담을 주고 있는 만큼, 안과용 레이저 시장은 앞으로도 지속적인 전략적 중요성을 유지할 것으로 전망됩니다. 임상적 근거, 정밀 공학, 디지털 통합 및 서비스 제공이 융합되는 분야에서 가장 큰 비즈니스 기회가 창출될 것입니다.
The Ophthalmic Lasers Market is projected to grow by USD 2.09 billion at a CAGR of 5.42% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.44 billion |
| Estimated Year [2026] | USD 1.52 billion |
| Forecast Year [2032] | USD 2.09 billion |
| CAGR (%) | 5.42% |
Ophthalmic lasers are central to modern eye care because they enable precise photocoagulation, photodisruption, photoablation, and selective tissue targeting across retina, glaucoma, cornea, cataract, and refractive procedures. Demand is structurally supported by the global burden of avoidable vision loss: the World Health Organization reports that at least 2.2 billion people have near or distance vision impairment, and at least 1 billion cases are preventable or remain unaddressed.
The market is being shaped by aging populations, rising diabetes prevalence, expanding ambulatory surgery infrastructure, and patient preference for minimally invasive eye procedures. Key ophthalmic laser technologies include femtosecond lasers, excimer lasers, Nd:YAG systems, diode lasers, selective laser trabeculoplasty platforms, pattern scanning lasers, and emerging image-guided laser systems. For manufacturers, distributors, and care providers, competitive differentiation increasingly depends on clinical precision, workflow efficiency, service uptime, software integration, regulatory compliance, and evidence-backed outcomes.
The ophthalmic laser landscape is shifting from standalone energy platforms toward digitally integrated, procedure-specific ecosystems. Retina practices are adopting pattern scanning and navigated photocoagulation to improve treatment consistency, while glaucoma specialists continue to use selective laser trabeculoplasty as evidence supports its role as a first-line or early intervention option for open-angle glaucoma in appropriate patients.
Refractive and cataract-related applications are also evolving. Femtosecond lasers have expanded precision in corneal flap creation, lenticule extraction, arcuate incisions, capsulotomy, and lens fragmentation, while excimer lasers remain established in corneal reshaping. At the same time, purchasing decisions are becoming more value-based, with hospitals and ambulatory surgery centers evaluating total cost of ownership, patient throughput, maintenance contracts, training needs, and reimbursement alignment.
Another defining shift is the movement toward compact, interoperable, and image-guided platforms. Providers increasingly expect integration with optical coherence tomography, electronic health records, diagnostic imaging, and treatment planning tools. This transition favors suppliers that can combine hardware reliability with software-led clinical decision support and remote service capabilities.
Artificial intelligence is exerting a cumulative impact across the ophthalmic laser value chain rather than replacing clinical judgment. AI-enabled image analysis is widely studied in diabetic retinopathy, age-related macular degeneration, glaucoma, and anterior segment assessment, creating a foundation for more accurate patient selection and treatment planning before laser intervention.
In clinical workflows, AI can support segmentation of retinal layers, identification of treatment zones, risk stratification, and longitudinal monitoring. When connected with optical coherence tomography, fundus photography, visual field data, and intraoperative imaging, AI may help clinicians tailor laser parameters, reduce variation, and improve follow-up prioritization. The strongest near-term value lies in workflow triage, documentation assistance, predictive maintenance, and decision support under physician oversight.
For industry leaders, the opportunity is constrained by data quality, explainability, cybersecurity, regulatory requirements, and liability management. Successful AI integration in ophthalmic lasers will depend on validated datasets, prospective clinical evidence, transparent algorithms, and compliance with medical device software regulations, including U.S. software guidance and the European Union Medical Device Regulation.
Asia-Pacific is one of the most important adoption environments for ophthalmic lasers because it combines large populations, high cataract and refractive correction demand, increasing diabetes prevalence, and rapid expansion of private eye hospitals. China, India, Japan, South Korea, Australia, and ASEAN markets are driving adoption through tertiary ophthalmology centers, specialty chains, academic hospitals, and technology-forward refractive surgery providers.
North America remains a high-value region supported by advanced clinical guidelines, strong adoption of premium surgical technologies, regulated medical device innovation, and a dense base of ophthalmologists, ambulatory surgery centers, and academic hospitals. The United States leads regional purchasing momentum, while Canada contributes through publicly funded care pathways and specialty centers focused on retina, glaucoma, cataract, and refractive care.
Europe benefits from well-established ophthalmic care networks, strong research capabilities, and demand for evidence-based medical devices under the EU MDR framework. Latin America, led by Brazil and Mexico, is expanding through private specialty clinics and improving access to retina and cataract care. The Middle East, particularly GCC countries, is investing in advanced hospital infrastructure and medical tourism, while Africa shows long-term potential as eye-care capacity, clinical training, and equipment access improve against a high burden of preventable vision impairment.
ASEAN is emerging as a strategic cluster for ophthalmic lasers as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand specialty care capacity. Singapore anchors advanced clinical adoption and training, while larger population markets are driven by cataract, diabetic eye disease, glaucoma, and refractive correction needs.
The GCC is characterized by high healthcare spending per capita, modernization of hospital networks, and demand for premium ophthalmology services in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. These markets favor advanced laser platforms with strong service support, physician training, regulatory documentation, and integration into high-acuity hospital and specialty clinic environments.
The European Union remains influential because regulatory clearance, clinical evidence, vigilance, and post-market surveillance under MDR shape global supplier standards. BRICS countries offer scale, with China and India driving procedure volume, Brazil supporting Latin American demand, Russia maintaining established urban ophthalmology centers, and South Africa serving as a regional hub. G7 countries represent mature, innovation-intensive markets with high expectations for safety, usability, and outcomes. NATO markets overlap significantly with North America and Europe, where procurement resilience, cybersecurity, device connectivity, and supply chain assurance are increasingly relevant for connected medical devices.
The United States is the leading country environment for ophthalmic lasers due to its large ophthalmology provider base, advanced ambulatory surgery ecosystem, active medical device regulatory pathway, and strong demand for retina, glaucoma, cataract, and refractive procedures. Canada follows with stable specialty care adoption and strong clinical governance, while Mexico benefits from private ophthalmology investment and cross-border care dynamics. Brazil is Latin America's largest healthcare market and a key adopter of retina and cataract laser technologies.
In Europe, the United Kingdom, Germany, France, Italy, and Spain represent mature ophthalmic device environments with established hospital systems and private specialty networks. Germany is particularly important for engineering, ophthalmic research, and technology adoption, while the United Kingdom and France emphasize evidence-based procurement and clinical governance. Russia maintains large urban ophthalmology centers, although procurement conditions can be affected by policy and supply chain constraints.
In Asia-Pacific, China and India offer substantial procedure opportunities because of population scale, rising diabetes burden, cataract prevalence, and expanding specialty hospital chains. Japan and South Korea are advanced markets with high clinical sophistication and strong refractive, retina, and cataract capabilities. Australia combines high standards of care with steady demand across cataract, glaucoma, retina, and corneal applications.
Industry leaders should prioritize clinically differentiated ophthalmic laser platforms that improve precision, safety, throughput, and reproducibility across high-volume eye procedures. Product strategy should align with major disease burdens, especially cataract, diabetic retinopathy, glaucoma, retinal disease, and refractive errors.
Companies should strengthen evidence generation through multicenter studies, real-world performance data, health-economic analysis, and post-market surveillance. Commercial success will also depend on service reliability, application training, consumable strategy, financing models, and integration with imaging and practice management systems.
AI-enabled functions should be introduced with clear clinical validation, explainable outputs, cybersecurity safeguards, and physician-in-the-loop workflows. Manufacturers should also localize market access strategies by matching product configuration, price architecture, regulatory submissions, and service networks to regional purchasing behavior.
This executive summary is developed using a structured secondary research methodology focused on verified public and industry-recognized sources. Inputs include epidemiological data from global health agencies, demographic indicators, medical device regulatory frameworks, clinical practice trends, ophthalmology society guidance, peer-reviewed literature, product approvals, and healthcare infrastructure indicators.
The analysis triangulates disease burden, procedure relevance, technology adoption, regulatory pathways, regional healthcare capacity, and competitive positioning. Qualitative validation is applied by comparing trends across multiple independent sources and excluding unsupported claims, speculative figures, and non-verifiable assumptions.
Market interpretation emphasizes data-backed drivers such as aging populations, diabetes prevalence, cataract and refractive procedure demand, ambulatory surgery growth, technology integration, and physician adoption patterns. The methodology is designed to support decision-making for manufacturers, distributors, investors, and healthcare providers.
The ophthalmic lasers market is positioned for sustained strategic relevance as vision impairment, diabetes-related retinal disease, glaucoma, cataract, and refractive correction needs continue to place pressure on eye-care systems. The strongest opportunities will emerge where clinical evidence, precision engineering, digital integration, and service execution converge.
Regional growth will not be uniform. Mature markets will reward innovation, workflow efficiency, and outcomes data, while emerging markets will prioritize access, affordability, training, and reliable support. Artificial intelligence will increasingly influence screening, planning, monitoring, and maintenance, but adoption will depend on regulatory confidence and clinical validation.
Organizations that invest in differentiated laser platforms, integrated imaging, AI-ready software, robust compliance, and localized market strategies will be best positioned to capture value in the evolving global ophthalmic lasers industry.